基于因子分析的附子理中方对脾虚泄泻的治疗作用及关键因子研究
|
摘要
目的:研究附子理中方对脾虚泄泻大鼠模型的治疗作用,同时采用因子分析法分析其治疗环节的关键因子。方法:大黄水煎液灌胃30 d建立脾虚泄泻大鼠模型,以附子理中方干预21天后,酶联免疫吸附(ELISA)法检测各组大鼠血清、血浆和组织中血管活性肠肽(VIP)、胃泌素(GAS)、胃动素(MTL)、白细胞介素1(IL-1)、白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)、干扰素γ(IFN-γ)、超氧化物歧化酶(SOD)和丙二醛(MDA)等指标的含量,同时通过因子分析方法综合分析提取附子理中方治疗脾虚泄泻的关键因子。结果:附子理中方能明显降低大鼠稀便率,在胃肠激素调节方面,具有升高GAS、MTL,降低VIP的作用,在免疫细胞因子的调节方面,具有降低IL-1、IL-6、TNF-α、IFN-γ的作用,在自由基的调节方面,具有降低MDA含量,维持SOD活性的作用。通过因子分析,从9个指标中抽提出2个公因子,共解释信息占92.61%,同时构建了脾虚泄泻模型综合评价函数。结论:附子理中方具有减少胃肠液分泌、保护胃黏膜、减轻炎症反应、减少自由基生成的作用。免疫因子和胃肠激素因子为附子理中方调节脾虚证的关键因子。对附子理中方不同剂型的作用进行比较发现,长期给药后,丸剂与汤剂在以上作用无明显差异,但丸剂在IFN-γ的调节上,效果优于汤剂。因子分析可以对脾虚泄泻模型进行综合评价,是一种适宜中医动物模型的评价方法。
Objective: To study the therapeutic effect and key factors of FuziLizhong prescription on Pixuxiexie rats by factor analysis method. Methods: Pixuxiexie rat model was established by oral administration of Rhubarb decoction for 30 days. After the model was established, FuziLizhong prescription was administered for 21 days. The contents of VIP, GAS, MTL, IL-1, IL-6, TNF-α, IFN-γ, SOD and MDA in serum, plasma and tissues of rats in each group were detected by ELISA. At the same time, the key factors of treating Pixuxiexie syndrome were analyzed by factor analysis. Result: FuziLizhong prescription decreased the diarrhea rate in rats, it also increased gastrointestinal hormone related factors GAS, MTL and decreased VIP. It reduced immune cell cytokines IL-1, IL-6, TNF-α and IFN-γ. It also reduced the content of free radicals MDA and maintained SOD activity. Two common factors were extracted from nine indexes by factor analysis, which explained 92.613% of the information and a comprehensive evaluation function of Pixuxiexie model was constructed. Conclusion: FuziLizhong prescription has the effects of reducing gastrointestinal secretion, protecting gastric mucosa, alleviating inflammation and reducing free radical production. Immunological factor and gastrointestinal hormone factor are the key factors of regulating Pixuxiexie syndrome. Comparing the effects of different formulations of FuziLizhong prescription,it shows no significant difference between pills and decoctions after long-term administration, but the effect of regulating IFN-γ is better in dosage form of pills than decoctions. Pixuxiexie model can be comprehensively evaluated by factor analysis, which may be a suitable evaluation method for animal models of traditional Chinese medicine.
Objective: To study the therapeutic effect and key factors of FuziLizhong prescription on Pixuxiexie rats by factor analysis method. Methods: Pixuxiexie rat model was established by oral administration of Rhubarb decoction for 30 days. After the model was established, FuziLizhong prescription was administered for 21 days. The contents of VIP, GAS, MTL, IL-1, IL-6, TNF-α, IFN-γ, SOD and MDA in serum, plasma and tissues of rats in each group were detected by ELISA. At the same time, the key factors of treating Pixuxiexie syndrome were analyzed by factor analysis. Result: FuziLizhong prescription decreased the diarrhea rate in rats, it also increased gastrointestinal hormone related factors GAS, MTL and decreased VIP. It reduced immune cell cytokines IL-1, IL-6, TNF-α and IFN-γ. It also reduced the content of free radicals MDA and maintained SOD activity. Two common factors were extracted from nine indexes by factor analysis, which explained 92.613% of the information and a comprehensive evaluation function of Pixuxiexie model was constructed. Conclusion: FuziLizhong prescription has the effects of reducing gastrointestinal secretion, protecting gastric mucosa, alleviating inflammation and reducing free radical production. Immunological factor and gastrointestinal hormone factor are the key factors of regulating Pixuxiexie syndrome. Comparing the effects of different formulations of FuziLizhong prescription,it shows no significant difference between pills and decoctions after long-term administration, but the effect of regulating IFN-γ is better in dosage form of pills than decoctions. Pixuxiexie model can be comprehensively evaluated by factor analysis, which may be a suitable evaluation method for animal models of traditional Chinese medicine.
引文
[1]李亚欢,张冬梅,王淑艳,等.脾虚证动物模型研制概况 .中医药导报,2019,25(1)∶100～102.
[2]陆英杰,连至诚.胃肠激素对胃肠动力的影响.免疫学杂志,2006,22(s1)∶94～96.
[3]王颖,郑小伟,李秀月.模拟中医病因所致脾气虚、脾阳虚大鼠模型的证候比较研究.中华中医药学刊,2012,30(1)∶104～107.
[4]徐世军,汤朝晖,李秀亮,等.益气增液颗粒对脾虚泄泻大鼠血清胃泌素及血浆胃动素影响的研究.中国中西医结合消化杂志,2003,11(1)∶9～11.
[5]徐珊,杨青,成信法,等.乐胃饮对脾虚实验大鼠胃泌素和胃动素的影响.中华中医药杂志,2004,19(1)∶20～22.
[6]Simren M,Bjornsson E S,Abrahamsson H.High interdigestive and postprandial motilin levels in patients with the irritable bowel syndrome.Neurogastroenterol Motil,2005,17(1)∶51～57.
[7]杨舒,钱会南.中医脾虚证的免疫机制研究进展.辽宁中医杂志,2008,35(9)∶1433～1435.
[8]曲长江,刘劲.五种脾虚小鼠模型过氧化与抗氧化改变的比较研究.辽宁中医杂志,2000,27(7)∶329～331.
[9]杨卢玲,徐艳秋.附子理中丸治疗脾肾阳虚型小儿厌食病.光明中医,2018,33(12)∶1699～1701.
[10]李丽.参苓白术散联合附子理中丸治疗脾虚型腹泻临床研究.亚太传统医药,2017,13(6)∶142～143.
[11]杨爱莉.附子理中丸治疗脾肾阳虚型五更泻132例疗效观察.亚太传统医药,2012,8(8)∶77～78.
[12]张文通,唐汉庆,王勇,等.附子理中丸增强脾阳虚证大鼠适应性产热.中国药师,2010,13(7)∶918～921.
[13]张文通,王晓怡,杨艳,等.附子理中丸对脾阳虚证大鼠骨骼肌肌球蛋白ATP酶活性的影响.中华中医药杂志,2011,26(3)∶490～494.
[14]武志娟,谭玮璐,张大鹏,等.附子理中汤对腹泻型肠易激综合征模型大鼠结肠黏膜NALP-3炎性体等免疫指标的调节作用.中药材,2018,41(4)∶971～975.
[15]李东安,王普民,贾冬,等.附子理中丸的药理作用研究 .中成药,1990,12(5)∶25～26.
[16]韦祎,唐汉庆,李晓华,等.附子理中汤对脾阳虚证大鼠免疫细胞因子的影响.中国实验方剂学杂志,2013,19(21)∶179～182.
[17]唐汉庆,韦祎,李晓华,等.附子理中汤对脾阳虚大鼠AQP4的影响及其止泻机制.中国实验方剂学杂志,2013,19(12)∶222～225.
[18]陈启光,申春悌,张华强,等.因子分析在中医证候规范标准研究中的应用.中国中医基础医学杂志,2004,10(8)∶53～56.
[19]李兵,王忠,张莹莹,等.中医证候分类研究常用方法与应用概述.中国中医基础医学杂志,2014,20(1)∶30～33.
[20]潘新,胡昌江,耿媛媛,等.脾肾阳虚泄泻大鼠模型造模方法研究.中国中药杂志,2014,39(23)∶4658～4663.
[21]崔宁,赵文晓,韩冰冰,等.基于因子分析的大鼠脾虚水湿不化模型评价研究.中国中医基础医学杂志,2016,22(1)∶35～37.
[22]沈娟,唐于平,李淑娇,等.基于因子分析的甘遂-甘草反药组合量-毒关系研究.中华中医药杂志,2015,30(5)∶1531～1537.
[23]任乃刚,陈伟,彭勃,等.整肠生的作用机制及临床应用.中国临床药理学杂志,2013,29(9)∶716～717.
[24]司继刚,李爱杰.蒙脱石散的合理规范使用.儿科药学杂志,2018,24(8)∶62～64.
[25]张臻,高天慧,傅超美,等.中药丸剂剂型理论与应用现状关键问题分析.中国中药杂志,2017,42(12)∶2408～2412.
[26]江茂源,张臻,石金凤,等.基于甘草中2种成分同时测定的附子理中丸溶出行为研究.中国中药杂志,2018,43(5)∶952～958.
[2]陆英杰,连至诚.胃肠激素对胃肠动力的影响.免疫学杂志,2006,22(s1)∶94～96.
[3]王颖,郑小伟,李秀月.模拟中医病因所致脾气虚、脾阳虚大鼠模型的证候比较研究.中华中医药学刊,2012,30(1)∶104～107.
[4]徐世军,汤朝晖,李秀亮,等.益气增液颗粒对脾虚泄泻大鼠血清胃泌素及血浆胃动素影响的研究.中国中西医结合消化杂志,2003,11(1)∶9～11.
[5]徐珊,杨青,成信法,等.乐胃饮对脾虚实验大鼠胃泌素和胃动素的影响.中华中医药杂志,2004,19(1)∶20～22.
[6]Simren M,Bjornsson E S,Abrahamsson H.High interdigestive and postprandial motilin levels in patients with the irritable bowel syndrome.Neurogastroenterol Motil,2005,17(1)∶51～57.
[7]杨舒,钱会南.中医脾虚证的免疫机制研究进展.辽宁中医杂志,2008,35(9)∶1433～1435.
[8]曲长江,刘劲.五种脾虚小鼠模型过氧化与抗氧化改变的比较研究.辽宁中医杂志,2000,27(7)∶329～331.
[9]杨卢玲,徐艳秋.附子理中丸治疗脾肾阳虚型小儿厌食病.光明中医,2018,33(12)∶1699～1701.
[10]李丽.参苓白术散联合附子理中丸治疗脾虚型腹泻临床研究.亚太传统医药,2017,13(6)∶142～143.
[11]杨爱莉.附子理中丸治疗脾肾阳虚型五更泻132例疗效观察.亚太传统医药,2012,8(8)∶77～78.
[12]张文通,唐汉庆,王勇,等.附子理中丸增强脾阳虚证大鼠适应性产热.中国药师,2010,13(7)∶918～921.
[13]张文通,王晓怡,杨艳,等.附子理中丸对脾阳虚证大鼠骨骼肌肌球蛋白ATP酶活性的影响.中华中医药杂志,2011,26(3)∶490～494.
[14]武志娟,谭玮璐,张大鹏,等.附子理中汤对腹泻型肠易激综合征模型大鼠结肠黏膜NALP-3炎性体等免疫指标的调节作用.中药材,2018,41(4)∶971～975.
[15]李东安,王普民,贾冬,等.附子理中丸的药理作用研究 .中成药,1990,12(5)∶25～26.
[16]韦祎,唐汉庆,李晓华,等.附子理中汤对脾阳虚证大鼠免疫细胞因子的影响.中国实验方剂学杂志,2013,19(21)∶179～182.
[17]唐汉庆,韦祎,李晓华,等.附子理中汤对脾阳虚大鼠AQP4的影响及其止泻机制.中国实验方剂学杂志,2013,19(12)∶222～225.
[18]陈启光,申春悌,张华强,等.因子分析在中医证候规范标准研究中的应用.中国中医基础医学杂志,2004,10(8)∶53～56.
[19]李兵,王忠,张莹莹,等.中医证候分类研究常用方法与应用概述.中国中医基础医学杂志,2014,20(1)∶30～33.
[20]潘新,胡昌江,耿媛媛,等.脾肾阳虚泄泻大鼠模型造模方法研究.中国中药杂志,2014,39(23)∶4658～4663.
[21]崔宁,赵文晓,韩冰冰,等.基于因子分析的大鼠脾虚水湿不化模型评价研究.中国中医基础医学杂志,2016,22(1)∶35～37.
[22]沈娟,唐于平,李淑娇,等.基于因子分析的甘遂-甘草反药组合量-毒关系研究.中华中医药杂志,2015,30(5)∶1531～1537.
[23]任乃刚,陈伟,彭勃,等.整肠生的作用机制及临床应用.中国临床药理学杂志,2013,29(9)∶716～717.
[24]司继刚,李爱杰.蒙脱石散的合理规范使用.儿科药学杂志,2018,24(8)∶62～64.
[25]张臻,高天慧,傅超美,等.中药丸剂剂型理论与应用现状关键问题分析.中国中药杂志,2017,42(12)∶2408～2412.
[26]江茂源,张臻,石金凤,等.基于甘草中2种成分同时测定的附子理中丸溶出行为研究.中国中药杂志,2018,43(5)∶952～958.